NeuroMetrix, Inc. (NASDAQ:NURO) Short Interest Update

NeuroMetrix, Inc. (NASDAQ:NURO) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,600 shares, a decrease of 36.0% from the February 28th total of 2,500 shares. Based on an average daily volume of 18,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. GTS Securities LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned about 1.12% of NeuroMetrix as of its most recent filing with the Securities & Exchange Commission. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

NeuroMetrix Price Performance

Shares of NASDAQ:NURO traded down $0.08 during trading on Friday, reaching $4.43. 2,608 shares of the company’s stock traded hands, compared to its average volume of 17,481. The company has a 50 day moving average of $4.35 and a 200-day moving average of $4.15. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The stock has a market capitalization of $9.09 million, a P/E ratio of -0.97 and a beta of 2.15.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of NeuroMetrix in a research report on Friday. They set a “sell” rating for the company.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.